This application seeks support for the activities of the Eastern Cooperative Oncology Group (ECOG) at the UW Paul P. Carbone Comprehensive Cancer Center (UWCCC). Over the past 30 years, the UWCCC has maintained exemplary main institution accrual and strong affiliate participation while providing high quality data and key scientific leadership. Institutional evaluations consistently rank the UW ECOG program at or near the top in categories of accrual, administrative, and scientific leadership. The basic, translational, and clinical research programs of the UWCCC are designed to reduce the cancer burden on the population by improving prevention, early detection, and treatment of cancer. The UWCCC commitment to cancer care and research has never been stronger. During the current grant cycle, we have tripled our clinical space and doubled our research space, representing an institutional commitment of nearly $100 million, and increased our cancer focused faculty by nearly 50%. The UWCCC faculty views the NCI cooperative groups as essential components in the war on cancer. Translation of scientific discovery to human populations and to individual patients requires an ability to conduct large scale clinical trials in a timely fashion. ECOG provides this vital forum and the UWCCC remains highly committed to its mutually beneficial partnership with ECOG.
ECOG clinical trials are a vitally important cancer treatment option for the citizens of Wisconsin. Group trials represent a proven system for improving outcomes for patients affected by cancer and the University of Wisconsin and its ECOG affiliates remain enthusiastic participants in the cooperative group system.
|Ganjoo, Kristen; Hong, Fangxin; Horning, Sandra J et al. (2014) Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 55:768-72|
|Liu, Glenn; Chen, Yu-Hui; Kolesar, Jill et al. (2013) Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol 31:211-8|
|Brahmer, Julie R; Dahlberg, Suzanne E; Gray, Robert J et al. (2011) Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 459 J Thorac Oncol 6:103-8|
|Landry, Jerome; Catalano, Paul J; Staley, Charles et al. (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101:587-92|
|Traynor, Anne M; Lee, Ju-Whei; Bayer, Gerald K et al. (2010) A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Invest New Drugs 28:91-7|
|Hussain, Maha; Goldman, Bryan; Tangen, Cathy et al. (2009) Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 27:2450-6|
|Dreicer, Robert; Li, Hailun; Stein, Mark et al. (2009) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 115:4090-5|
|Keedy, Vicki; Wang, Wei; Schiller, Joan et al. (2008) Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597. J Clin Oncol 26:4166-71|
|Ignatoff, Jeffrey M; Chen, Yu-Hui; Greenberg, Richard Evan et al. (2008) Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group. Urol Oncol :|
|Meyerhardt, Jeffrey A; Niedzwiecki, Donna; Hollis, Donna et al. (2008) Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol 26:4109-15|
Showing the most recent 10 out of 124 publications